免疫调节性寡聚脱氧核苷酸筛选方法的建立、优化和应用

目的:建立一套合理而便捷的实验体系,为开发新型免疫调节性寡聚脱氧核苷酸(ODN)提供筛选方法。方法:利用含有CpG基序的免疫刺激性寡聚脱氧核苷酸(CpG ODN)作为刺激物,将人外周血单个核细胞(PBMC)作为研究对象,分别以细胞的增殖程度和刺激上清的抗病毒活性作为检测指标,优化各项实验条件,综合评定寡聚脱氧核苷酸的免疫调节活性。结果:成功建立了由阳性免疫调节性ODNA151抑制CpG ODN诱导的人PBMC增殖及抗病毒活性的筛选方法。结论:免疫调节性ODN筛选方法的成功建立,为下一步研究开发新型免疫调节性ODN奠定了基础。     

Gene therapy for pituitary tumors

Pituitary tumors are the most common primary intracranial neoplasms. Although most pituitary tumors are considered typically benign, others can cause severe and progressive disease. The principal aims of pituitary tumor treatment are the elimination or reduction of the tumor mass, normalization of hormone secretion and preservation of remaining pituitary function. In spite of major advances in the therapy of pituitary tumors, for some of the most difficult tumors, current therapies that include medical, surgical and radiotherapeutic methods are often unsatisfactory and there is a need to develop new treatment strategies. Gene therapy, which uses nucleic acids as drugs, has emerged as an attractive therapeutic option for the treatment of pituitary tumors that do not respond to classical treatment strategies if the patients become intolerant to the therapy. The development of animal models for pituitary tumors and hormone hypersecretion has proven to be critical for the implementation of novel treatment strategies and gene therapy approaches. Preclinical trials using several gene therapy approaches for the treatment of anterior pituitary diseases have been successfully implemented. Several issues need to be addressed before clinical implementation becomes a reality, including the development of more effective and safer viral vectors, uncovering novel therapeutic targets and development of targeted expression of therapeutic transgenes. With the development of efficient gene delivery vectors allowing long-term transgene expression with minimal toxicity, gene therapy will become one of the most promising approaches for treating pituitary adenomas.     

Effects of behavior modification on body image, depression and body fat in obese Korean elementary school children

This study was performed to investigate the effects of behavior modification on body image, depression and body fat in obese elementary school children. Sixty-two elementary students of the 4th to 6th grade were selected from two different Seoul schools. Thirty-four children in one school were designated as the experimental group, and 28 children from the other school as the control group. The experimental group received 60 - 70 minutes of behavior modification, once a week, for 8 weeks. The control group received neither management nor treatment. The results indicated a significant improvement of body image and a reduction in the increase rate of body fat for the experimental group. This finding strongly supports the theory that behavior modification can be used as an effective strategy in the treatment of obese children.     

趋化性细胞因子对人Tc1和Tc2细胞内Ca~(2+)浓度变化的影响

为了探讨趋化性细胞因子在体外对人Tc1和Tc2亚群细胞内Ca2 + 浓度变化的影响 ,从PBMC中分离纯化CD8+ T细胞 ,在特定细胞因子及细胞因子抗体作用下 ,体外定向诱导出能长期培养的Tc1和Tc2细胞系 ,用免疫荧光染色结合流式细胞术分析对其进行鉴定后 ,通过流式细胞术检测在趋化性细胞因子刺激前后 ,细胞内Ca2 + 浓度的变化。发现受SDF 1作用后 ,Tc1及Tc2细胞内Ca2 + 浓度变化均不明显 ,而IP 10刺激后 ,Tc1及Tc2细胞内Ca2 + 水平在短时间内明显上调 ,且在Tc1胞内的上升幅度远高于Tc2细胞 ,在MIP 1β刺激后 ,也观察到类似趋势 ;受Eotaxin刺激后 ,Tc1及Tc2细胞内Ca2 + 水平均有微小上升 ,在Tc2细胞内的上升幅度略高于Tc1细胞。说明Tc1和Tc2细胞受趋化性细胞因子作用后 ,细胞内Ca2 + 浓度有不同程度的变化 ,且与趋化性细胞因子受体的表达呈现一定的相关性。     

AMPK通过增强心肌脂肪酸氧化抑制大鼠心肌肥厚

目的： 探讨单磷酸腺苷（AMP）激活的蛋白激酶（AMPK）对心肌肥厚的影响及可能涉及的作用机制。方法： 通过对大鼠行腹主动脉缩窄术（TAC）引起压力负荷增加，造成心肌肥厚的模型。术后24 h起经皮下注射AMPK的特异性激活剂AICAR(0.5 mg·kg-1·d-1)直至术后7周。处死动物前，对大鼠进行超声心动学指标的检测和血清游离脂肪酸浓度测定；处死动物，取心脏称重后计算心脏重/体重比值，测量心肌细胞的平均直径、心肌中的游离脂肪酸含量、过氧化体增殖物激活型受体α（PPARα）和肉碱棕榈酰转移酶（CPT-I）的mRNA表达。结果： （1）心肌肥厚+AICAR组大鼠的心脏重/体重比值、心肌细胞平均直径、血清及心肌中游离脂肪酸的浓度明显低于心肌肥厚对照组；（2）心肌肥厚+AICAR组大鼠心肌PPARα及CPT-I的mRNA表达明显高于心肌肥厚对照组；(3) 心肌肥厚+AICAR组大鼠心脏超声心动学指标：左室后壁舒张末期厚度、左室舒张、收缩末期内径 (PWT, LVDD, LVSD) 低于心肌肥厚对照组，左室短轴缩短率 (FS%) 则高于心肌肥厚对照组。结论： 活化的AMPK可能通过增强心肌脂肪酸氧化从而抑制压力负荷增加引起的心肌肥厚。     

胎牛血清外泌体对成骨细胞增殖的作用

背景:研究表明外泌体具有促进骨再生的能力,但从胎牛血清中提取的外泌体是否可以促进骨形成仍存在争议。目的:观察胎牛血清外泌体对成骨细胞增殖能力的影响,从而为临床治疗骨破坏提供新思路。方法:通过超速离心法从胎牛血清中提取外泌体,采用透射电子显微镜和Western blot法验证外泌体是否提取成功;然后用10 mg/L胎牛血清外泌体干预成骨前体细胞MC3T3-E1,通过CCK-8实验检测外泌体对成骨细胞增殖能力的影响,Western blot检测外泌体对成骨细胞骨形态发生蛋白2和骨桥蛋白表达的影响。以不含外泌体的胎牛血清培养的MC3T3-E1细胞为对照组。结果与结论:①胎牛血清外泌体具有典型的脂质双层膜结构,大小在30-150 nm之间,外泌体表面标记因子CD81表达呈阳性,而微囊表面标记物CD40表达呈阴性;②外泌体组的增殖能力明显高于对照组,差异有显著性意义(P<0.05);外泌体组成骨标志性因子骨形态发生蛋白2和骨桥蛋白的表达水平明显高于对照组,差异有显著性意义(P<0.05);③结果表明,胎牛血清外泌体对成骨细胞的增殖起促进作用,可为临床治疗骨破坏提供新思路。     

Autologous stem cell transplantation in the treatment of refractory rheumatoid arthritis

The concept of using high-dose immunosuppressive treatment (HDIT) with autologous stem cell transplantation (ASCT) to treat patients with refractory rheumatoid arthritis has been provided by animal studies and anecdotal case reports. Over the past five years, an increasing number of patients with refractory rheumatoid arthritis have received HDIT with ASCT as an adjunct to intense immunosuppression. Here, we present a case of refractory rheumatoid arthritis in a 54-yr-old woman using HDIT with ASCT. Peripheral blood stem cells were mobilized with cyclophosphamide (4 g/m(2)) followed by G-CSF (5 microg/kg/day). Leukapheresis continued daily until the number of harvested progenitor cells reached 2 x 10(6) CD34+ cells/kg after CliniMax CD34+ positive selection. For HDIT, high-dose cyclophosphamide (total dose 200 mg/kg) and antithymocyte globulin (total dose 90 mg/kg) were administered and CD34+ cells were infused 24 hr after HDIT. The patient tolerated the treatment well but experienced an episode of neutropenic fever. She achieved an early dramatic improvement of joint symptoms during therapy. Fifty percent of improvement of rheumatoid arthritis by the American College of Rheumatology (ACR 50) preliminary definition was fulfilled during the 6 months following ASCT. Although further long-term follow-up is required, the patient's activity of arthritis has been stable since receiving HDIT with ASCT.     

人α2（I）型胶原基因启动子活性研究

目的 探索器官纤维化形成中调控I型胶原基因高水平转录的启动片段及TGF-β、PDGF－BB、IGF－1等细胞因子对其活性的影响。方法 从人α2（I）胶原基因转录起始点上游－2.4kb至＋58bp的片段中，取长度不等的片段作为启动子与含氯霉素乙酰基转移酶（CAT）报告基因的质粒组成5个重组体，转染上述重组体至正常人原代培养皮肤成纤维细胞，测定细胞CAT表达水平以比较各重组体的启动子活性，同时加入细胞因子，以测定其对I型胶原启动序列的影响。结果 除－129～＋58bp序列外，其余4个重组体CAT表达水平均较高，其中－2292～＋58bp、－1476～ 58bp序列具较强启动CAT表达活性，－339～ 58bp、－616～ 58bp片段次之。TGF－β、IGF－1均能在一定程度上调人α2（I）胶原基因启动活性。结论 人α2（I）胶原基因片段－2292～ 58bp、－1476～ 58bp、－339～ 58bp有高启动活性，是进一步研究纤维化相关DNA结合蛋白的重要调控靶序列。TGF－β、IGF－1促进胶原表达，与其上调胶原基因启动活性有关。     

Purification and characterization of placental heparanase and its expression by cultured cytotrophoblasts

The role of different extracellular matrix (ECM)-degrading enzymesin the normal functioning of the placenta is well documented.Heparan sulphate proteoglycan (HSPG) is an integral constituentof the placental and decidual ECM. Because this proteoglycanspecifically interacts with various macromolecules in the ECM,its degradation may disassemble the matrix. Hence, in the caseof the placenta, this may facilitate normal placentation andtrophoblast invasion. Crude placental specimens were collectedfrom first and third trimester placentas. Heparanase (endo-P-glucuronidase)was isolated and purified by ammonium sulphate precipitationfollowed by sequential chromatographies on carboxymethyl-, heparin-and ConA-Sepharose columns. The placental enzyme was furthercharacterized for its molecular weight and specific inhibitionby heparin, and was shown to resemble heparanase expressed byhighly metastatic tumour cells and activated cells of the immunesystem. In order to locate the source of heparanase activityin the placenta, primary cytotrophoblast cultures were established.Intact cells, as well as conditioned medium and cell lysates,were analysed for heparanase activity using metabolically sulphate-labelledECM as a natural substrate. Heparanase was highly active inlysates of cytotrophoblasts. This activity was also expressedby intact cytotrophoblasts seeded on ECM, but no activity couldbe detected in the culture medium. Incubation of the cytotrophoblastsin contact with ECM resulted in release of ECM-bound basic fibroblastgrowth factor (bFGF). We propose that the cytotrophoblasticheparanase facilitates placentation, through cytotrophoblastextravasation and localized neovascularization. cytotrophoblast/extracellular matrix/heparanase/heparan sulphate proteoglycan/placenta